Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Although a 2007 meta-analysis first sounded the alarm about rosiglitazone's cardiovascular risks, the manufacturer successfully stalled regulatory action in the U.S. Health Policy Fellowship Department of Family Medicine Georgetown University School of Medicine The size of average doses would more than triple.
130 
Let's personalize your content